DEVELOPMENT OF LACIDIPINE TRANSFEROSOMAL FORMULATIONS FOR TRANSDERMAL DELIVERY: IN VIVO CHARACTERIZATION IN RATS
DOI:
https://doi.org/10.22159/ijap.2025v17i2.52830Keywords:
Lacidipine, Transdermal drug delivery, Transferosomes, Ex-vivo permeation, Pharmacodynamic activity, Pharmacokinetic activityAbstract
Objective: Lacidipine is a calcium channel blocker prescribed to treat hypertension. Due to first-pass metabolism, the drug has low bioavailability via oral route. The present research aims to enhance bioavailability by developing lacidipine-loaded transferosomes for transdermal delivery and evaluate their efficacy in a rat model.
Methods: Transferosomes were prepared by thin film hydration technique and characterized for physicochemical properties. Permeation studies across rat skin were carried out using Franz diffusion cells. Pharmacodynamic and Pharmacokinetic studies were conducted on male Wister rats. The optimized transferosomal formulation (F3L) contains soya lecithin, tween 80 and drug in proportion of 85:15:4 with labrasol (2%) as permeation enhancer.
Results: The optimized formulation exhibited a vesicle size of 132.6 nm, Polydispersity index (PDI) of 0.174, zeta potential of-33.7 mV and entrapment efficiency 97.5%. The steady-state flux of optimized formulation (F3L) and drug suspension was 83.1µg/cm2/h and 16.9 µg/cm2/h, respectively. The flux of F3L was significantly high (P<0.0001,4.92 times) compared with drug suspension. Scanning electron microscopic images showed spherical-shaped transferosomes. The antihypertensive activity was carried out in fructose-induced rats by tail cuff method. The transferosomal formulation F3L significantly decreased systolic blood pressure (P<0.0001) compared to an oral drug suspension. The antihypertensive effect of transdermal formulation was sustained for up to 24 h. The bioavailability of optimized transferosomal formulation was 3.37 folds compared to oral lacidipine suspension. The histopathological study confirmed the safety of transferosomes.
Conclusion: The results confirmed the potential advantage of employing transferosomes as suitable nanocarriers for the transdermal delivery of lacidipine.
References
Kjeldsen SE. Hypertension and cardiovascular risk: general aspects. Pharmacol Res. 2018;129:95-9. doi: 10.1016/j.phrs.2017.11.003, PMID 29127059.
Missiriya SM, John J. Assess the prevalence of hypertension and knowledge regarding the prevention of stroke. Asian J Pharm Clin Res. 2017 Apr;10(8):177-80. doi: 10.22159/ajpcr.2017.v10i8.18558.
Baishya BI, Rahman SS, Rynjah DA, Barman KA, Bordoloi SS, Islam JA. Enhancing of oral bioavailability of poorly water-soluble antihypertensive drugs. Int J Curr Pharm Sci. 2021 Jul;13(4):42-7. doi: 10.22159/ijcpr.2021v13i4.42741.
Sharma M, Sharma R, Jain DK. Nanotechnology-based approaches for enhancing oral bioavailability of poorly water-soluble antihypertensive drugs. Scientifica. 2016 Apr;2016(3):8525679. doi: 10.1155/2016/8525679, PMID 27239378.
De Luca MD, Ioele G, Spatari C, Ragno G. Photodegradation of 1, 4-dihydropyridine antihypertensive drugs: an updated review. Int J Pharm Pharm Sci. 2018 Dec;10(1):8-18. doi: 10.22159/ijpps.2018v10i1.22562.
Opie LH, Krum HE, Victor RG, Kaplan NM. Antihypertensive therapies. In: Opie LH, Gersh B, editors. Drugs for the heart. 8th ed. Philadelphia: Elsevier; 2013. p. 224-71. doi: 10.1016/B978-1-4557-3322-4.00016-8.
Reddy YK, Reddy DM, Kumar MA. Transdermal drug delivery system: a review. IJRPB. 2014 Mar;2(2):1094-103.
Upadhyay G, Verma S, Parvez N, Sharma PK. Recent trends in transdermal drug delivery system: a review. Adv Biol Res. 2014 Jan;20148(3):131-8.
Pawar PM, Solanki KP, Mandali VA. Recent advancements in transdermal drug delivery system. Int J Pharm Clin Res. 2018 Mar;10(3):65-73.
Jalajakshi MN, Chandrakala V, Srinivasan S. Recent development in transdermal drug delivery: an overview. Int J Pharm Pharm Sci. 2022 Oct;14(10):1-9.
Kumar RS, kumar PK. An overview on ultra deformable vesicular drug delivery systems in transdermal drug delivery. Int J Appl Pharm. 2023 May;15(3):28-34.
Kumar PK, Kumar RS. Review on transferosomes and transferosomal gels. J Pharm Res Int. 2021 Sep;33(43B):114-26. doi: 10.9734/jpri/2021/v33i43B32532.
Opatha SA, Titapiwatanakun V, Chutoprapat R. Transfersomes: a promising nanoencapsulation technique for transdermal drug delivery. Pharmaceutics. 2020 Sep;12(9):855. doi: 10.3390/pharmaceutics12090855, PMID 32916782.
Namrata M, Vijeta B, Alagusundaram M. Transferosomes: the effective targeted drug delivery system overview. J Pharm Negat Results. 2022 Dec;13(8):4316-21.
Nagaraju PT, Channabasavaraj KP, Kumar PT. Development and validation of spectrophotometric method for estimation of lacidipine in tablet dosage form. Int J PharmTech Res. 2011 Jan;3(1):18-23.
Muralidharan S. High performance liquid chromatographic method development and its validation for lacidipine. Int J PharmTech Res. 2013 Jan;5(1):79-85.
Guan J, Huan X, Liu Q, Jin L, Wu H, Zhang X. Synergetic effect of nucleation and crystal growth inhibitor on in vitro-in vivo performance of supersaturable lacidipine solid dispersion. Int J Pharm. 2019 Jul;566(9):594-603. doi: 10.1016/j.ijpharm.2019.06.010, PMID 31175988.
Velupula S, Velupula R, Janapareddi K. Formulation and characterization of glibenclamide loaded transferosomal gel for transdermal delivery. Eur Chem Bull. 2023;12(4):5536-51.
Pasha I, Khan AB, Sudheer P. Formulation and evaluation of transdermal ultradeformable vesicles of aspirin. Acta Pharm Sci. 2022 Aug;60(4):389-412. doi: 10.23893/1307-2080.APS6025.
Guo P, Li N, Fan L, Lu J, Liu B, Zhang B. Study of penetration mechanism of labrasol on rabbit cornea by ussing chamber, RT-PCR assay, Western blot and immunohistochemistry. Asian J Pharm Sci. 2019 May;14(3):329-39. doi: 10.1016/j.ajps.2018.05.005, PMID 32104463.
Ahad A, Al-Saleh AA, Al-Mohizea AM, Al-Jenoobi FI, Raish M, Yassin AE. Formulation and characterization of Phospholipon 90 G and tween 80-based transfersomes for transdermal delivery of eprosartan mesylate. Pharm Dev Technol. 2018 Sep;23(8):787-93. doi: 10.1080/10837450.2017.1330345, PMID 28504046.
Ahad A, Aqil M, Kohli K, Sultana Y, Mujeeb M, Ali A. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan. Nanomedicine. 2012 Feb;8(2):237-49. doi: 10.1016/j.nano.2011.06.004, PMID 21704600.
Nurfitriyana N, Harmita H, Iskandarsyah I. In vitro study of a transferosomal gel preparation containing lynestrenol as a transdermal drug delivery system. Int J Appl Pharm. 2020 Mar;12(1):242-4.
Pavani K, Babu MK. Formulation and evaluation of lornoxicam transferosomes as carriers for effective transdermal drug delivery. IJRPB. 2015 Nov;3(6):416-22.
Jangdey MS, Gupta A, Saraf S, Saraf S. Development and optimization of apigenin-loaded transfersomal system for skin cancer delivery: in vitro evaluation. Artif Cells Nanomed Biotechnol. 2017 Jan;45(7):1452-62. doi: 10.1080/21691401.2016.1247850, PMID 28050929.
Balata GF, Faisal MM, Elghamry HA, Sabry SA. Preparation and characterization of ivabradine HCl transfersomes for enhanced transdermal delivery. J Drug Deliv Sci Technol. 2020 Dec;60(1):101921. doi: 10.1016/j.jddst.2020.101921.
Nippani AD, Janapareddi K. Development and ex-vivo evaluation of atorvastatin microemulsions for transdermal delivery using box-behnken design. Int J Pharm Biol Sci. 2018 Jul;8(3):81-93.
Onah CM, Mbah CJ, Attama AA. Studies on transdermal delivery of irbesartan: microemulsion as a delivery system. Int J Pharm Sci Res. 2018 Dec;9(12):5463-73.
Albash R, Abdelbary AA, Refai H, El-Nabarawi MA. Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Int J Nanomedicine. 2019 Mar;14:1953-68. doi: 10.2147/IJN.S196771, PMID 30936696.
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv. 2016;23(2):395-404. doi: 10.3109/10717544.2014.914986, PMID 24865287.
Dai S, McNeill JH. Fructose-induced hypertension in rats is concentration and duration-dependent. J Pharmacol Toxicol Methods. 1995 Apr;33(2):101-7. doi: 10.1016/1056-8719(94)00063-a, PMID 7766916.
Hwang IS, Ho H, Hoffman BB, Reaven GM. Fructose-induced insulin resistance and hypertension in rats. Hypertension. 1987 Nov;10(5):512-6. doi: 10.1161/01.hyp.10.5.512, PMID 3311990.
Salem HF, El-Menshawe SF, Khallaf RA, Rabea YK. A novel transdermal nanoethosomal gel of lercanidipine HCl for treatment of hypertension: optimization using box-benkhen design, in vitro and in vivo characterization. Drug Deliv Transl Res. 2020 Feb;10(1):227-40. doi: 10.1007/s13346-019-00676-5, PMID 31625026.
Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm. 2015 Dec;41(12):1968-77. doi: 10.3109/03639045.2015.1024685, PMID 25830370.
Gannu R, Palem CR, Yamsani VV, Yamsani SK, Yamsani MR. Enhanced bioavailability of lacidipine via microemulsion based transdermal gels: formulation optimization, ex vivo and in vivo characterization. Int J Pharm. 2010 Mar;388(1-2):231-41. doi: 10.1016/j.ijpharm.2009.12.050, PMID 20060457.
Qadri GR, Ahad A, Aqil M, Imam SS, Ali A. Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017 Feb;45(1):139-45. doi: 10.3109/21691401.2016.1138486, PMID 26829018.
Nagaraju PG, Sengupta P, Chicgovinda PP, Rao PJ. Nanoencapsulation of clove oil and study of physicochemical properties, cytotoxic, hemolytic, and antioxidant activities. J Food Process Engineering. 2021 Apr;44(4):e13645. doi: 10.1111/jfpe.13645.
Published
How to Cite
Issue
Section
Copyright (c) 2025 SARITHA DUNAKA, KRISHNAVENI JANAPAREDDI
This work is licensed under a Creative Commons Attribution 4.0 International License.
